S9912 Combination Chemo in Stage III Ovarian Cancer,

Phase 2 Completed 68 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, cisplatin, and liposomal doxorubicin in treating women who have undergone surgery for stage III ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Timeline

Start: 1999-09
Primary completion: 2008-02
Completion: 2008-02

Publications

Results Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M. Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. Gynecol Oncol. 2009 Aug;114(2):206-9. doi: 10.1016/j.ygyno.2009.04.023. Epub 2009 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cisplatin	Other / unclassified	75 mg/m2	Other
Subject	Doxorubicin	Other / unclassified	30 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	40 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	60 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	135 mg/m2	Intravenous

S9912 Combination Chemo in Stage III Ovarian Cancer,

Summary

Timeline

Publications

Drugs

Indications